News | Heart Valve Technology | February 10, 2016

Chicago Bulls’ Coach Fred Hoiberg Leads New Heart Valve Patient Education Campaign

NBA head coach shares personal experience as heart valve patient, receiving an On-X Aortic Heart Valve in 2015

Fred Hoiberg, Chicago Bulls coach, On-X aortic heart valve, education campaign

Fred Hoiberg, head coach of the NBA Chicago Bulls, is launching a new campaign to help people with heart valve problems on www.heartvalvesurgery.com. Coach Hoiberg, pictured here with his family, wanted a single, life-long solution to his aortic heart valve problem, and received an On-X aortic mechanical valve from On-X Life Technologies Inc. in April 2015.

On-X Aortic Heart Valve, Fred Hoiberg, Chicago Bulls

The On-X Aortic Heart Valve from On-X Life Technologies Inc. is the only mechanical heart valve FDA-cleared to allow patients to reduce blood thinner medication to nearer normal levels.

February 10, 2016 — Fred Hoiberg, head coach of the National Basketball Assocation’s (NBA) Chicago Bulls, is launching a new patient education campaign featuring a video recounting his experience as a heart valve patient. The video premiered January 14 on www.HeartValveSurgery.com.

A 10-year NBA veteran who had played for the Indiana Pacers, Chicago Bulls and Minnesota Timberwolves, Hoiberg had open-heart surgery in April 2015 to replace his failing bicuspid aortic heart valve, a heredity structural malformation that had been causing increasing fatigue and shortness-of-breath.

The campaign, designed to help people with heart valve problems learn more about their condition and treatment options, is sponsored by On-X Life Technologies Inc., the company that made Coach Hoiberg’s aortic replacement heart valve. The full video is available here.

Hoiberg, who had an open-heart surgery a decade earlier to address life-threatening problems with an aortic aneurysm, was seeking a single, life-long solution to his aortic valve problem and agreed when his doctor recommended he receive an On-X Aortic Heart Valve.

“The On-X valve is expected to last throughout my lifetime, so I don’t have to worry about the possibility of future re-operations, which would have been likely if I’d received a tissue valve,” Hoiberg said. “I also didn’t want to put my family through all of the stress related to needing additional surgeries in the future.”

“Tissue valves last longer in older people and are less durable in younger people, and there are risks with every subsequent reoperation for valve failure,” said Marc Gerdisch, M.D., chief of cardiovascular and thoracic surgery at Franciscan St. Francis Heart Center in Indianapolis.

“If Coach Hoiberg had, at his age and physical activity level, received a tissue valve instead of the On-X aortic heart valve, he’d likely have needed another one, and even another one after that during his lifetime,” Gerdisch said, adding that most tissue valves are documented to fail structurally in 15 years or fewer in patients younger than age 60.

While some patients may choose replacement valves made of animal tissue in hopes of avoiding taking the blood-thinning medication warfarin, many patients also require warfarin therapy in order to manage their other health conditions, such as atrial fibrillation (AFib).

“I’ve heard that some people have concerns about taking blood-thinning medication after getting a mechanical valve, but it hasn’t been an issue for me. I’m very physically active, yet I haven’t had to make any major changes in either my activities or my diet because I’m taking blood-thinners,” said Hoiberg.

Gerdisch added that patients with On-X aortic heart valves are the only ones in the United States who have been allowed by the U.S. Food and Drug Administration (FDA) to reduce their blood-thinning medications to “near normal” levels.

“In a multi-year clinical study, we demonstrated that patients who had received an On-X aortic heart valve could be safely and effectively managed at much lower levels of blood thinner medication. Our findings showed that there are significant reductions in complications with the On-X valve when compared to any other valve, whether mechanical or tissue,”1 said Gerdisch, who also served as a principal investigator of the PROACT (Prospective Randomized On-X Anticoagulation Clinical Trial) study. “The On-X valve is a genuine innovation and the only mechanical valve that I implant.”

On-X replacement heart valves are bileaflet prosthetic valves made of pure pyrolytic carbon. Clinical evaluations have shown that the On-X Aortic Heart Valve features a unique material and design, which have been clinically documented to have lower complications than other mechanical heart valves.

For more information: www.onxvalve.com

Related Content

Left, the Melody pulmonary valve was the first transcatheter valve to be approved by the FDA in the United States a decade ago. Right, the Harmony transcatheter valve is in trials and is designed to treat patients with RVOT anomalies who develop severe PR typically when a pervious repair fails. Both valves are used to treat congenital heart defects. #SCAI #SCAI2020

Left, the Melody pulmonary valve was the first transcatheter valve to be approved by the FDA in the United States a decade ago. Right, the Harmony transcatheter valve is in trials and is designed to treat patients with RVOT anomalies who develop severe PR typically when a pervious repair fails. Both valves are used to treat congenital heart defects.

News | Congenital Heart | May 21, 2020
May 21, 2020 — Two late-breaking clinical trials on trans catheter valves to treat congenital heart disease were pres
SCAI Issues Position Statement on Adult Congenital Cardiac Interventional Training, Competencies and Organizational Recommendations. A congenital atrial septal defect closed using a transcatheter occluder, visualized on 3-D TEE ultrasound.

A congenital atrial septal defect closed using a transcatheter occluder, visualized on 3-D TEE ultrasound.

News | Congenital Heart | May 04, 2020
University of Arizona Leads Statewide Study of Congenital Heart Defects
News | Congenital Heart | October 24, 2019
Investigators at the University of Arizona Steele Children's Research Center are leading a statewide study as part of a...
Abbott Receives European CE Mark for Two Pediatric Heart Devices
News | Congenital Heart | September 20, 2019
Abbott announced approvals in Europe for two of its pediatric devices — the Masters HP 15mm rotatable mechanical heart...
High Blood Pressure, Cholesterol in Young Adults Associated With Later Heart Disease
News | Congenital Heart | July 16, 2019
Elevated blood pressure and cholesterol levels in young adulthood may lead to an increased risk of heart disease later...
Hypertension Found in Children Exposed to Flower Pesticides
News | Congenital Heart | June 03, 2019
Researchers at University of California San Diego School of Medicine found higher blood pressure and pesticide...
Edwards Recalls Miller and Fogarty Balloon Dilation Atrioseptostomy Catheters
News | Congenital Heart | April 29, 2019
Edwards Lifesciences is recalling the Miller Balloon Atrioseptostomy Catheter and Fogarty Dilation Atrioseptostomy...
New Pediatric Blood Pressure Guidelines Improve Premature Heart Disease Identification
News | Congenital Heart | April 22, 2019
New guidelines that classified more children as having elevated blood pressure  are better at predicting which kids are...
Better Options Needed for Children at Higher Risk of Premature Heart Disease
News | Congenital Heart | February 28, 2019
Obesity and severe obesity in childhood and adolescence have been added to the list of conditions that put children and...
Climate Change May Increase Congenital Heart Defects
News | Congenital Heart | January 30, 2019
Rising temperatures stemming from global climate change may increase the number of infants born with congenital heart...